ORIENT BIO Inc. (KRX:002630)
562.00
+17.00 (3.12%)
At close: Nov 26, 2025
ORIENT BIO Revenue
ORIENT BIO had revenue of 17.21B KRW in the quarter ending December 31, 2021, with 21.77% growth. This brings the company's revenue in the last twelve months to 59.09B, up 19.53% year-over-year. In the fiscal year ending March 31, 2021, ORIENT BIO had annual revenue of 52.02B with 39.79% growth.
Revenue (ttm)
59.09B
Revenue Growth
+19.53%
P/S Ratio
1.13
Revenue / Employee
472.73M
Employees
125
Market Cap
66.64B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2021 | 52.02B | 14.81B | 39.79% |
| Mar 31, 2020 | 37.21B | 6.84B | 22.52% |
| Mar 31, 2019 | 30.37B | 4.75B | 18.53% |
| Mar 31, 2018 | 25.62B | -83.39B | -76.50% |
| Mar 31, 2017 | 109.02B | 3.97B | 3.78% |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |